|
Tipo |
Publicación |
| 3 |
Periódico |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 36 |
Periódico |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
| 59 |
Periódico |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 63 |
Periódico |
Marquardt Ed, Lam SSY.
Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 811-812. |
| 81 |
Periódico |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Periódico |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Periódico |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 132 |
Periódico |
Najari Z, Rusho WJ.
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Am J Health-Syst Pharm 1997 ; 54: 181-184. |
| 169 |
Periódico |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 176 |
Periódico |
Mantong ML, Marquardt ED.
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2567-2568. |
| 182 |
Periódico |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Periódico |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Periódico |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Periódico |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 261 |
Periódico |
Percy LA, Rho JP.
Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 715-716. |
| 266 |
Periódico |
Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 299 |
Periódico |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Periódico |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Periódico |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Periódico |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 335 |
Periódico |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 386 |
Periódico |
Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358. |
| 397 |
Periódico |
Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126. |
| 467 |
Periódico |
Ishisaka DY, van Vleet J, Marquardt E.
Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion.
Am J Hosp Pharm 1991 ; 48: 2442-2443. |
| 479 |
Periódico |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 496 |
Periódico |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 503 |
Periódico |
Nahata MC, Durrell DE.
Stability of tobramycin sulfate in admixtures with calcium gluconate.
Am J Hosp Pharm 1985 ; 45: 1987-1988. |
| 612 |
Periódico |
Frable RA, Klink PR, Engel GL, Mundell EE.
Stability of cefamandole nafate injection with parenteral solutions and additives.
Am J Hosp Pharm 1982 ; 39: 622-627. |
| 619 |
Periódico |
Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ.
Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives.
Am J Hosp Pharm 1982 ; 39: 1013-1015. |
| 706 |
Periódico |
Cutie MR.
Compatibility of verapamil hydrochloride with other additives.
Am J Hosp Pharm 1981 ; 38: 231. |
| 730 |
Periódico |
Allen LV, Saul Levinson R, Phisutsinthop D.
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Am J Hosp Pharm 1977 ; 34: 939-943. |
| 789 |
Periódico |
Garner SS, Wiest DB.
Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system.
Am J Hosp Pharm 1990 ; 47: 604-606. |
| 813 |
Periódico |
Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68. |
| 905 |
Periódico |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Periódico |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 939 |
Periódico |
Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1041 |
Periódico |
Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951. |
| 1058 |
Periódico |
Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.
Am J Hosp Pharm 1983 ; 40: 1690-1691. |
| 1084 |
Periódico |
Raupp P, von Kriek R, Schmidt E, Pfahl HG, G?nther O.
Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies.
Lancet 1988 ; 1(8587): 700. |
| 1165 |
Periódico |
Bowtle WJ, Heasman MJ, Prince AP, Easthope DA.
Compatibility of the cephalosporin, cefamandole nafate with injections.
Int J Pharm 1980 ; 4: 263-265. |
| 1193 |
Periódico |
Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ.
Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.
Am J Hosp Pharm 1983 ; 40: 1010-1012. |
| 1232 |
Periódico |
Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1236 |
Periódico |
Kuhn RJ, Nahata MC.
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Am J Hosp Pharm 1986 ; 43: 1241-1242. |
| 1315 |
Periódico |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
| 1410 |
Periódico |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Periódico |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Periódico |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1490 |
Periódico |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
| 1496 |
Periódico |
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428. |
| 1611 |
Periódico |
Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1625 |
Periódico |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Periódico |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1712 |
Periódico |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Periódico |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Periódico |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1754 |
Periódico |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1802 |
Periódico |
Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194. |
| 1803 |
Periódico |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1914 |
Laboratorio |
Pemetrexed (Alimta®) - Summary of Product Characteristics
Eli Lilly 2016 |
| 1925 |
Periódico |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 |
Periódico |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 2087 |
Periódico |
Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20. |
| 2090 |
Periódico |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2108 |
Periódico |
Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232. |
| 2109 |
Periódico |
Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75. |
| 2262 |
Periódico |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Periódico |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 2295 |
Laboratorio |
Fosaprepitant (Emend®) - Summary of Product Characteristics
Merck Sharp Dohme 2013 |
| 2302 |
Laboratorio |
Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium.
Lettre AFFSAPS 30 November 2008 2008 ; 61, 5: 356-357. |
| 3012 |
Periódico |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3152 |
Periódico |
Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3210 |
Periódico |
Jasti Bhaskara R, Saraf Poonam.
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Int J Pharm Compound 2011 ; 15, 3: 259-261. |
| 3216 |
Periódico |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Periódico |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 |
Periódico |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3268 |
Periódico |
Beauregard N, Bertrand N, Dufour A, Blaizel O, Leclair G
Physical compatibility of calcium gluconate and magnesium sulfate injections.
Am J Health-Syst Pharm 2012 ;69: 98. |
| 3408 |
Periódico |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3429 |
Periódico |
Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Am J Health-Syst Pharm 2015 ; 72:483-486 |
| 3523 |
Laboratorio |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018 |
| 3526 |
Laboratorio |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3546 |
Laboratorio |
Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007 |
| 3619 |
Laboratorio |
Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics
Wockhardt 2016 |
| 3621 |
Laboratorio |
Phosphate dipotassique - Résumé des caractéristiques du produit
Renaudin 2008 |
| 3644 |
Laboratorio |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3662 |
Laboratorio |
Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014 |
| 3753 |
Laboratorio |
Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics
Cubist Pharmaceuticals 2014 |
| 3766 |
Periódico |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
Periódico |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3824 |
Periódico |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
Póster |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
Póster |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
Póster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3838 |
Laboratorio |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 3883 |
Laboratorio |
Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016 |
| 3933 |
Laboratorio |
Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit
Teva Laboratoire 2015 |
| 3964 |
Periódico |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 4055 |
Periódico |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 |
Periódico |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4154 |
Laboratorio |
Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018 |
| 4319 |
Periódico |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4433 |
Periódico |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4434 |
Periódico |
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170. |
| 4491 |
Periódico |
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2020 |
| 4528 |
Periódico |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4538 |
Periódico |
Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K.
Compatibility of pentoxifylline and parenteral medications.
Archives of Disease in Childhood 2020 ; 105: 395-397. |
| 4603 |
Periódico |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4650 |
Laboratorio |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
| 4651 |
Periódico |
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2021 ;180,1169–1176. |
| 4654 |
Póster |
Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021 |
| 4720 |
Laboratorio |
Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021.
Paratek Pharmaceuticals 2021 |
| 4742 |
Periódico |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4802 |
Laboratorio |
Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit
Aguettant Laboratory 2021 |
